KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata, Hiroki Hara, Hironaga Satake, Masazumi Takahashi, Atsushi Takeno, Hiroo Imai, Keiko Minashi, Takeshi Kawakami, Shogen Boku, Jin Matsuyama, Yasuhiro Sakamoto, Kentaro Sawada, Masato Kataoka, Hisato Kawakami, Toshio Shimokawa, Narikazu Boku, Taroh Satoh

J Clin Oncol 43(19) 2196-2207

PMID40408613
PMCIDPMC12199805
DOI10.1200/JCO.24.01119
发表日期2025-05-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Continuous use of antiangiogenic agents has demonstrated survival benefits in various cancers. This trial aimed to compare the efficacy and safety of ramucirumab plus irinotecan with irinotecan monotherapy as a third- or later-line treatment for patients with advanced or recurrent gastric or gastroesophageal cancer (AGC) that has progressed on previous ramucirumab-based chemotherapy. METHODS: Patients age 20 years and older with AGC, who had experienced disease progression during ramucirumab-based chemotherapy, were randomly assigned to receive either ramucirumab plus irinotecan or irinotecan monotherapy. The primary end point was overall survival (OS) expecting a hazard ratio (HR) of 0.77 (a power of 80% and a significance level of one-sided 0.05). Secondary end points included progression-free survival (PFS), response rate, disease control rate (DCR), and safety. RESULTS: Between February 2017 and August 2022, 402 patients in Japan were randomly assigned to receive ramucirumab plus irinotecan (n = 202) or irinotecan monotherapy (n = 200). The median OS was 9.4 months in the combination arm and 8.5 months in the monotherapy arm, with an adjusted HR of 0.91 (95% CI, 0.74 to 1.12; P = .49). PFS was improved (median, 3.8 v 2.8 months; HR, 0.72 [95% CI, 0.59 to 0.89]; P = .002), while the DCR was significantly better (64.4% v 52.1%; P = .03) with the combination therapy. The adverse events of the combination therapy were manageable. CONCLUSION: Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.

KM 提取结果

3 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. Kaplan-Meier curve of (A) OS and (B) PFS in patients with advanced gastric cancer receiving ramucirumab plus irinotecan or irinotecan monotherapy. OS, overall survival; PFS, progression-free survival.

A

OS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
B

PFS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIG A2.

FIG A2. Kaplan-Meier curves for (A) OS and (B) PFS in the intention-to-treat population. OS, overall survival; PFS, progression-free survival.

A

OS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG A2. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:short span曲线 2:very low support曲线 2:off origin start
查看结果
KM Figure2 个面板

FIG A3.

FIG A3. Kaplan-Meier curves for (A) OS and (B) PFS in the per-protocol set population. OS, overall survival; PFS, progression-free survival.

A

OS

FIG A3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG A3. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram of the study. ITT, intention-to-treat.
非 KM Figure
FIG 3.FIG 3. Forest plot of (A) OS and (B) PFS in patients with advanced gastric cancer receiving ramucirumab plus irinotecan or irinotecan monotherapy. HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG A1.FIG A1. Waterfall plot of (A) the ramucirumab plus irinotecan group and (B) the irinotecan monotherapy group.
非 KM Figure